- Home
- Publications
- Publication Search
- Publication Details
Title
Biomarkers of drugs targeting HER-family signalling in cancer
Authors
Keywords
-
Journal
JOURNAL OF PATHOLOGY
Volume 232, Issue 2, Pages 219-229
Publisher
Wiley
Online
2013-10-09
DOI
10.1002/path.4269
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abstract P5-18-09: A Phase I Study of MM-302, a HER2-targeted Liposomal Doxorubicin, in Patients with Advanced, HER2- Positive Breast Cancer
- (2014) T Wickham et al. CANCER RESEARCH
- Abstract S5-1: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC)
- (2014) J Baselga et al. CANCER RESEARCH
- Abstract P1-07-03: Quantification of HER2 expression at the single cell level and HER2 intratumoral heterogeneity of breast cancer tissue samples using automated image analysis
- (2014) E Geretti et al. CANCER RESEARCH
- Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications
- (2013) F. Montemurro et al. ANNALS OF ONCOLOGY
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
- (2013) M Cizkova et al. BRITISH JOURNAL OF CANCER
- Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial
- (2013) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006
- (2013) Mothaffar F. Rimawi et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer
- (2013) Sherene Loi et al. JNCI-Journal of the National Cancer Institute
- The Implications of Clonal Genome Evolution for Cancer Medicine
- (2013) Samuel Aparicio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation
- (2013) V. Serra et al. Cancer Discovery
- Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
- (2012) I. Vaz-Luis et al. ANNALS OF ONCOLOGY
- Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement
- (2012) S. Guiu et al. ANNALS OF ONCOLOGY
- Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
- (2012) C. Garcia-Garcia et al. CLINICAL CANCER RESEARCH
- Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity
- (2012) Kensuke Shiraishi et al. Gastric Cancer
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes
- (2012) Benjamin Haibe-Kains et al. JNCI-Journal of the National Cancer Institute
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Genetic heterogeneity and cancer drug resistance
- (2012) Nicholas C Turner et al. LANCET ONCOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
- (2012) Douglas G. Altman et al. PLOS MEDICINE
- Molecular Classification of Estrogen Receptor-positive/Luminal Breast Cancers
- (2011) Felipe C. Geyer et al. ADVANCES IN ANATOMIC PATHOLOGY
- PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
- (2011) J. D. Jensen et al. ANNALS OF ONCOLOGY
- PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
- (2011) Leiping Wang et al. BMC CANCER
- Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
- (2011) E. Razis et al. BREAST CANCER RESEARCH AND TREATMENT
- Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients
- (2011) Filippo Montemurro et al. CANCER
- Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers
- (2011) Timothy R. Wilson et al. CANCER CELL
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
- (2011) Mark Barok et al. CANCER LETTERS
- Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
- (2011) R. Ghosh et al. CANCER RESEARCH
- p95HER2 and Breast Cancer
- (2011) J. Arribas et al. CANCER RESEARCH
- Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
- (2011) Y. Yamashita-Kashima et al. CLINICAL CANCER RESEARCH
- Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: A Randomized Phase II Study
- (2011) C. K. Osborne et al. CLINICAL CANCER RESEARCH
- Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement
- (2011) Alan Mackay et al. JNCI-Journal of the National Cancer Institute
- Gene expression profiling in breast cancer: classification, prognostication, and prediction
- (2011) Jorge S Reis-Filho et al. LANCET
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
- (2011) J. T. Garrett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab
- (2010) Allan Lipton et al. CANCER
- A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast Cancers
- (2010) J. L. Parra-Palau et al. CANCER RESEARCH
- Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer with Acquired Endocrine Resistance
- (2010) A. F. Leary et al. CLINICAL CANCER RESEARCH
- Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo
- (2010) Z. A. Wainberg et al. CLINICAL CANCER RESEARCH
- Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
- (2010) M. Cristofanilli et al. CLINICAL CANCER RESEARCH
- Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients
- (2010) J. Sperinde et al. CLINICAL CANCER RESEARCH
- Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers
- (2010) Bhuvanesh Dave et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Breast cancer molecular profiling with single sample predictors: a retrospective analysis
- (2010) Britta Weigelt et al. LANCET ONCOLOGY
- Triple-negative breast cancer: disease entity or title of convenience?
- (2010) Lisa Carey et al. Nature Reviews Clinical Oncology
- Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver
- (2010) D. N. Amin et al. Science Translational Medicine
- Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling
- (2009) Christina Gewinner et al. CANCER CELL
- Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
- (2009) L. Liu et al. CANCER RESEARCH
- A Novel Proximity Assay for the Detection of Proteins and Protein Complexes: Quantitation of HER1 and HER2 Total Protein Expression and Homodimerization in Formalin-fixed, Paraffin-Embedded Cell Lines and Breast Cancer Tissue
- (2009) Yining Shi et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer
- (2009) Prithviraj Bose et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescencein situhybridization and microarray-based CGH analysis
- (2009) Caterina Marchiò et al. JOURNAL OF PATHOLOGY
- A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis
- (2009) K. Pedersen et al. MOLECULAR AND CELLULAR BIOLOGY
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
- (2009) Saskia M. Brachmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
- (2008) P. J.A. Eichhorn et al. CANCER RESEARCH
- A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
- (2008) C. L. Arteaga et al. CLINICAL CANCER RESEARCH
- Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
- (2008) Grazia Arpino et al. ENDOCRINE REVIEWS
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
- Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor–Positive Breast Cancers
- (2008) Marta Guix et al. JOURNAL OF CLINICAL ONCOLOGY
- Transforming Growth Factor Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab
- (2008) S. E. Wang et al. MOLECULAR AND CELLULAR BIOLOGY
- Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
- (2008) Qing-Bai She et al. PLoS One
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search